Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1979 Jun;42(6):576–579. doi: 10.1136/jnnp.42.6.576

Six month evaluation of thiopropazate hydrochloride in tardive dyskinesia.

J S Smith, L G Kiloh
PMCID: PMC490265  PMID: 381595

Abstract

Using a blind evaluation of cinematographic films of patients suffering from tardive dyskinesia we found that thiopropazate hydrochloride in a dosage up to 30 mg daily was effective in reducing the severity of the dyskinesia in most patients. The overall improvement in the group of patients studied was not significant after one or three months of therapy but was significant after six months of treatment. The administration of thiopropazate hydrochloride over a six month period did not appear to aggravate the underlying pathophysiology so that the drug could be considered likely to be safe for long-term use. The anticholinergic antiparkinsonism agent benztropine mesylate aggravated the dyskinesia to a significant degree.

Full text

PDF
576

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asnis G. M., Leopold M. A., Duvoisin R. C., Schwartz A. H. A survey of tardive dyskinesia in psychiatric outpatients. Am J Psychiatry. 1977 Dec;134(12):1367–1370. doi: 10.1176/ajp.134.12.1367. [DOI] [PubMed] [Google Scholar]
  2. Carroll B. J., Curtis G. C., Kokmen E. Paradoxical response to dopamine agonists in tardive dyskinesia. Am J Psychiatry. 1977 Jul;134(7):785–789. doi: 10.1176/ajp.134.7.785. [DOI] [PubMed] [Google Scholar]
  3. Casey D. E. Tardive dyskinesia: are there subtypes. N Engl J Med. 1976 Nov 4;295(19):1078–1078. doi: 10.1056/NEJM197611042951914. [DOI] [PubMed] [Google Scholar]
  4. Crane G. E. Persistent dyskinesia. Br J Psychiatry. 1973 Apr;122(569):395–405. doi: 10.1192/bjp.122.4.395. [DOI] [PubMed] [Google Scholar]
  5. Degkwitz R., Binsack K. F., Herkert H., Luxenburger O., Wenzel W. Zum Problem der persistierenden extrapyramidalen Hyperkinesen nach langfristiger Anwendung von Neuroleptika. Nervenarzt. 1967 Apr;38(4):170–174. [PubMed] [Google Scholar]
  6. Gerlach J., Reisby N., Randrup A. Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychopharmacologia. 1974 Jan 9;34(1):21–35. doi: 10.1007/BF00421217. [DOI] [PubMed] [Google Scholar]
  7. Kiloh L. G., Smith J. S., Williams S. E. Antiparkinson drugs as causal agents in tardive dyskinesia. Med J Aust. 1973 Sep 22;2(12):591–593. doi: 10.5694/j.1326-5377.1973.tb129673.x. [DOI] [PubMed] [Google Scholar]
  8. Klawans H. L., Jr The pharmacology of tardive dyskinesias. Am J Psychiatry. 1973 Jan;130(1):82–86. doi: 10.1176/ajp.130.1.82. [DOI] [PubMed] [Google Scholar]
  9. Quitkin F., Rifkin A., Gochfeld L., Klein D. F. Tardive dyskinesia: are first signs reversible? Am J Psychiatry. 1977 Jan;134(1):84–87. doi: 10.1176/ajp.134.1.84. [DOI] [PubMed] [Google Scholar]
  10. Roxburgh P. A. Treatment of persistent phenothiazine-induced oral dyskinesia. Br J Psychiatry. 1970 Mar;116(532):277–280. doi: 10.1192/bjp.116.532.277. [DOI] [PubMed] [Google Scholar]
  11. Singer K., Cheng M. N. Thiopropazate hydrochloride in persistent dyskinesia. Br Med J. 1971 Oct 2;4(5778):22–25. doi: 10.1136/bmj.4.5778.22. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES